Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
GSK awarding $400,000 to Greater Philadelphia nonprofits making an IMPACT on health outcomes
GSK today honored 10 local nonprofits that help foster a healthier Philadelphia region.
-
GSK awards Triangle nonprofits making a powerful IMPACT on health outcomes
Ten North Carolina nonprofits will each receive a $40,000 GSK IMPACT Award
-
GSK delivers sales of £9.4 billion +16% AER, +11% CER (Pro-forma +6% CER*)
GSK delivers sales of £9.4 billion +16% AER, +11% CER (Pro-forma +6% CER*)
-
GSK starts a phase III clinical programme for a potential first-in-class antibiotic, gepotidacin
First in a new chemical class of antibiotic with a mechanism of action distinct from any currently approved antibiotic.
-
GSK receives prestigious Prix Galien USA award for SHINGRIX
SHINGRIX recognized as 2019 Best Pharmaceutical Product, following Galien Award win in Germany last week.
-
GSK announces new events in the "Us in Lupus" campaign to reach women of color
The initiative complements the virtual Us in Lupus program, an online education program and community for people diagnosed with lupus.
-
GSK Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer
GSK Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib)...
-
GSK agrees to divest rabies and tick-borne encephalitis vaccines to Bavarian Nordic
GSK agrees to divest rabies and tick-borne encephalitis vaccines to Bavarian Nordic
-
GSK and Lyell Immunopharma join forces to develop the next generation of cancer cell therapies
Collaboration will combine Lyell’s technologies with GSK’s pipeline of cell therapies and manufacturing capability
-
GSK submits filing to FDA for Trelegy Ellipta use in patients with asthma
GSK submits filing to FDA for Trelegy Ellipta use in patients with asthma
-
IDWeek 2019: ViiV Healthcare to present 20 abstracts from its innovative R&D portfolio with focus on 2-drug and long-acting regimens and mental health impact of HIV
Presentations include six-year data for the investigational regimen of cabotegravir and rilpivirine.
-
Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer
Phase 3 PRIMA trial of Zejula® (niraparib)
-
GSK presents new data showing promising anti-tumour activity with GSK3359609, an ICOS receptor agonist, in combination with pembrolizumab in head and neck squamous cell carcinoma (HNSCC)
Data presented at ESMO 2019 support phase II/III registrational trial with pembrolizumab in first-line recurrent/metastatic HNSCC.
-
GSK invests $120 million in next-generation US biopharmaceutical manufacturing facility
GSK today announced a $120 million investment to expand its manufacturing facility in Upper Merion, Pennsylvania.
-
Real-world effectiveness evidence among GSK data presented at ERS 2019
Real-world effectiveness evidence among GSK data presented at ERS 2019
-
GSK receives positive CHMP opinion for intravenous Benlysta in children with lupus aged five years and above
GSK receives positive CHMP opinion for intravenous Benlysta in children with lupus aged five years and above.
-
Nucala is the first biologic approved in the US for six to 11-year-old children with severe eosinophilic asthma
Nucala is the first biologic approved in the US for six to 11-year-old children with severe eosinophilic asthma
-
GSK to present data from its innovative oncology portfolio at ESMO Congress 2019
GSK today announced that data from its growing oncology pipeline will be presented at the European Society for Medical Oncology Congress
-
GSK announces positive headline results from the pivotal DREAMM-2 study for multiple myeloma
Belantamab mafodotin (GSK2857916) on track for regulatory submission by the end of 2019
-
ViiV Healthcare reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months
ViiV Healthcare reports positive phase III study results
